BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer - Wikidata - wikimedia - TriplyDB

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

http://www.wikidata.org/entity/Q34919430

about

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.Molecular targeting of papillary thyroid carcinoma with fluorescently labeled ratiometric activatable cell penetrating peptides in a transgenic murine model BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature.Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation.Advances in small molecule therapy for treating metastatic thyroid cancer.Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance.Clinical guidance for radioiodine refractory differentiated thyroid cancer.Follicular cell-derived thyroid cancer.Novel targeted therapies and immunotherapy for advanced thyroid cancers.The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing.EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines.Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.Management of recurrent or metastatic thyroid cancer.Preoperative Molecular Markers in Thyroid Nodules.MEK inhibitors for the treatment of NRAS mutant melanoma

P2860

Q26751274-C73AD477-0CAA-457A-B601-D2AE051F3A91 Q26772015-7D5554B7-A8DD-4FB9-BEDA-11EC65E8DC75 Q35057314-183A08D7-FDAB-42AC-9B0F-AD972115F7FB Q36468764-1D4580C6-E381-447D-BA78-26B2697B870F Q37088201-D3CD6E93-4844-4B98-98FC-7BFB75C43AB1 Q37179943-753AA5A8-399E-4A2E-8257-F49405E1D2B8 Q38569221-3641C340-CA11-4797-A687-03A649169D7A Q38823954-4EEF9415-D22D-4EB2-86C6-8088B2AF8BEE Q38865611-B1FF49AF-2E53-4292-B498-885AB957E695 Q38883187-49C95A78-1BB0-415F-BADD-1ADAF2DBB442 Q39146689-A95AD1B5-BD89-457F-ADFA-65DBDC9FB5B6 Q39364787-2C8E1E3B-2B01-4933-BD01-662EC771BC8D Q41099951-F416F11A-0283-4CBC-8F0F-CB866CFB40D2 Q41418283-A16DB4EE-646A-483C-8FF4-C4287F7986F2 Q41665358-B13EB212-747B-4E2F-A395-94E075B5F228 Q47161687-3B3CBB69-080E-4F5E-BDBF-9B596AC9F632 Q47295202-A0DE54F5-3918-4B96-9A79-8EC21D836AA1 Q47863818-E45774F2-1FC9-4CA3-9E96-8863A6B7AE8F Q48651339-6F9DA76A-D371-4655-92BE-BB6EB7BCE5CE Q49887965-B2072A1F-1C6C-49AF-B027-4FB22EF8AA0B Q51560869-2767840C-2910-4F8A-B741-9498E96BF631 Q52608453-D0479018-FEC3-4F3F-94C3-104FFD237FFF Q53084563-EFB649AD-43BF-4E01-BA59-9B90737EDE64 Q54111658-76D024D3-2E2B-427C-91EA-8EDA5E661465 Q54979977-0A36F5DE-1D5A-4909-94B5-55E128CB8C88 Q55004266-CE9E95E7-D881-4CBA-B460-147A6DA1F573 Q56889985-ACD8A3CF-7F54-4CD7-82E1-7163EF141976

P2860

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

http://www.wikidata.org/entity/Q34919430

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

@ast

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

@en

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

@nl

type

label

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

@ast

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

@en

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

@nl

prefLabel

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

@ast

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

@en

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

@nl

P1433

Q34919430-622EFB39-88F0-4833-A9A4-7325BCA9C779

P1476

Q34919430-7BC8A10A-ABAE-4ECF-B620-7AE44F1DA0D8

P2093

Q34919430-261F41E8-797D-4D2B-A073-A826E435339C

Q34919430-28300BE9-6C6D-42D3-944E-8032FCB1A3A5

Q34919430-4F714F1E-380C-4BBA-91FD-616C48AF397C

Q34919430-5E1C576F-F9AE-4154-BB59-A78BCD685DB9

Q34919430-93F0C424-1B46-42DA-9169-2D5BB77ABF2A

Q34919430-95D1830A-4A7B-4EF6-9AC3-AA679100CBA0

Q34919430-A7BC5482-7D38-4A2D-BA6D-68E77918548D

Q34919430-E4B8C4D5-639D-4A5E-A244-6AD31AEE53C6

Q34919430-F52CF563-92FA-4CCD-B8C8-51D4A025E0EE

P2860

Q34919430-0E13772C-0987-4E20-ACBC-C92086AB80F2

Q34919430-16798318-D449-4E76-90D5-53F5E5B85E9E

Q34919430-284E1DD5-D900-4F03-AF9D-9C917D767057

Q34919430-37093310-E0F8-437B-99B4-F43C90A7337B

Q34919430-3C473B5F-EDA6-442A-A4EA-E0F9F9292694

Q34919430-3D5718F9-16DE-47AC-B7EC-9846837CDE5B

Q34919430-41C204EE-FAC5-4AE0-A8DB-069A2A3346D9

Q34919430-45AF10BE-A5AA-4244-9654-18E82F0DF054

Q34919430-4754E90E-8D19-49F0-8171-EAEA2AB9B2B6

Q34919430-4B16E9CE-6294-4933-B0DA-FBBB00C51DE7

P304

Q34919430-AFCC4CA2-6E28-4FF4-9472-A48BE4845807

P31

Q34919430-421116C7-C7FA-4F94-A6F4-B66474FFB7A4

P356

Q34919430-5AE288EB-7D51-4EA7-8A8D-ADF8385E7A5E

P433

Q34919430-6824C841-AB04-4600-A086-DAFBB5014074

P478

Q34919430-7D73C2C6-B838-46F0-A7C8-265199E01A44

P50

Q34919430-52CCF012-2602-42FD-B314-74D089C974BC

Q34919430-BABC5027-A61A-4799-9B92-C0E63A40E9BF

Q34919430-C498F5E4-02AD-44AB-B9A7-82A0F4F87D4C

P577

Q34919430-D144D7CD-53A0-4B03-9610-CEE007DA093C

P698

Q34919430-FAB58589-704A-493B-839D-4E5774CB66FE

P932

Q34919430-A21FE982-D75A-4257-993C-DFB624FA692D

P356

P1433

P1476

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

@en

P2093

Aung Naing

http://www.w3.org/2001/XMLSchema#string

Bo Ma

http://www.w3.org/2001/XMLSchema#string

David Hong

http://www.w3.org/2001/XMLSchema#string

Gerald S Falchook

http://www.w3.org/2001/XMLSchema#string

Maria E Cabanillas

http://www.w3.org/2001/XMLSchema#string

Martin Curtis

http://www.w3.org/2001/XMLSchema#string

Michael Millward

http://www.w3.org/2001/XMLSchema#string

Razelle Kurzrock

http://www.w3.org/2001/XMLSchema#string

Vicki Goodman

http://www.w3.org/2001/XMLSchema#string

P2860

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

P304

71-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/THY.2014.0123

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Steven I. Sherman

Sarina Piha-Paul

Steven G Waguespack

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25285888

http://www.w3.org/2001/XMLSchema#string

P932

4291160

http://www.w3.org/2001/XMLSchema#string